GEMCYTABIN (CYTOGEM®) AND CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED BLADDER CANCER: RESULTS OF A PROSPECTIVE OPEN-LABELED NON-COMPARATIVE NON-RANDOMIZED STUDY
<p><strong>Purpose</strong>. The primary end-points of the study were overall response rate, progressive-free and overall survival in patients received Gemcytabin (Cytogem®) and Cisplatin as first-line therapy for transitional-cell bladder cancer. Secondary end-points were toxicit...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-08-01
|
| Series: | Onkourologiâ |
| Subjects: | |
| Online Access: | http://oncourology.abvpress.ru/index.php/oncur/article/view/297 |
Search Result 1